Latest From Genitope Corp.
Talon Therapeutics has appointed Thomas DeZao head of commercial operations and planning function, ahead of Marqibo's (vincristine sulphate liposomes injection) 12 August PDUFA date. Mr DeZao's experience includes senior commercial and marketing positions related to hematologic cancer product candidates at ChemGenex Pharmaceuticals, Genitope Corporation and Corixa/Coulter Pharmaceuticals.
Pharmacyclics has received $150 million up front under a development and commercialisation deal with Johnson & Johnson unit Janssen Biotech for a first-in-class oral candidate for haematological malignancies currently in Phase II trials.
Biovest International's (Accentia Biopharmaceuticals) therapeutic cancer vaccine BiovaxID looks to have become the first to improve disease-free survival (DFS) in follicular lymphoma (FL) in the pivotal Phase III BV-301 study that was highlighted at a plenary session at the ASCO meeting in Orlando.
The world's first biotechnology company, Genentech, was founded in 1976. 30 years later there were 4,275 biotechnology companies worldwide, of which 710 were publicly listed. Dr Peter Charlish reviews the fortunes of the top 100 biotech companies involved in human healthcare on the basis of product sales and R&D investment
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Genitope Corp.
- Senior Management
Dan W Denney, Jr., PhD, CEO & Interim CFO
Tom DeZao, VP, Strategic Mktg. & Sales
Thomas P Theriault, PhD, VP, R&D
- Contact Info
Phone: (510) 284-3000
6900 Dumbarton Cr.
Freemont, CA 94555
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.